UnitedHealth overcharged cancer patients for drugs by over 1,000%

Ethics and Definition of “Overcharging”

• Many argue 10x–1000% markups on life‑saving drugs are self‑evidently exploitative, even if no “correct” margin is legally defined.
• A minority contend you can’t say “overcharge” without specifying a justifiable reference price (cost+, Medicaid rate, etc.), and push for more precise targets rather than moral outrage alone.

PBMs, Vertical Integration, and Gaming the Rules

• UnitedHealth’s structure (insurer + PBM + pharmacies + massive physician network) is seen as enabling internal price‑laundering: inflate drug and provider prices, then treat transfers as “medical spend” to satisfy Medical Loss Ratio (MLR) caps while retaining profit in sister entities.
• Similar concerns raised about other vertically integrated players (e.g., insurers owning PBMs and pharmacies like CVS/Aetna).
• PBMs are described as originally meant to negotiate lower prices and promote generics, but now accused of kickbacks, opaque spreads, and favoring high‑price drugs because rebates and percentage‑based fees grow with list price.

Insurance Profits and Cost Drivers

• One camp: private insurers’ net margins (~3–6%) and direct share of national health spending are small; the real cost problem is expensive providers, drugs, and overuse.
• Another camp: those low margins hide substantial rent extraction via vertical integration, administrative bloat, and inflated list prices; “profit %” is a misleading metric.
• Debate over administrative efficiency: some cite Medicare’s ~2% overhead vs >10% for private insurance; others argue those comparisons are skewed by population mix and accounting.

Systemic US Healthcare Failures

• Broad agreement that the US spends far more per capita than peers for worse outcomes and spotty coverage.
• Employer‑tied insurance, lack of meaningful choice, complex billing, opaque pricing, and claim denials are recurring complaints.
• Several note that non‑profit insurers and government programs also struggle with rising costs, implying problems extend beyond pure shareholder profit.

Market vs Regulation / Single‑Payer Debate

• Many advocate stronger regulation, antitrust “trust‑busting,” or full single‑payer / public option with universal risk pooling; they note other rich countries achieve better, cheaper care.
• Libertarian‑leaning commenters ask whether true free‑market competition has ever been allowed; others respond that healthcare’s inelastic, life‑or‑death nature makes pure markets inherently predatory.

Innovation and Profit Motive

• Some defend profit in pharma as necessary to fund risky, expensive R&D, while conceding much basic science is publicly funded and evergreening/patent games are common.
• There is near‑consensus that insurers and PBMs add little true “innovation” in care, mainly innovating in denial strategies, data harvesting, and financial engineering.

Lived Experiences and Employer Constraints

• Personal stories: IVF and specialty drugs costing far more through insurer‑owned pharmacies than cash; claim denials; surprise bills; a cancer death where coverage existed but bureaucracy added heavy burden.
• Employers report annual 15–20% premium hikes and sometimes choosing widely criticized insurers like UnitedHealth purely on short‑term cost, acknowledging this shifts pain to employees.